Per1 inhibitors are a class of chemical compounds that have garnered significant attention in the field of molecular biology and circadian rhythm research. These inhibitors specifically target the Period 1 (Per1) gene, which is a critical component of the circadian clock mechanism in most organisms, including humans. The circadian clock is a sophisticated biological timekeeping system that regulates various physiological processes, such as sleep-wake cycles, hormone secretion, and metabolism, to ensure that they follow a roughly 24-hour rhythm. Per1, along with other clock genes, plays a central role in the generation and maintenance of these circadian rhythms.
The Per1 gene codes for a protein known as PER1, which, in collaboration with other clock proteins, undergoes a complex cycle of synthesis and degradation to regulate circadian rhythms. Per1 inhibitors are designed to interfere with this cycle, typically by suppressing the expression or activity of PER1. By doing so, these inhibitors can disrupt the normal functioning of the circadian clock, leading to a range of effects on the organism's daily physiological and behavioral patterns. Researchers utilize Per1 inhibitors as valuable tools to manipulate and study circadian rhythms in experimental settings. Understanding the precise mechanisms by which Per1 inhibitors impact the circadian clock can provide insights into the broader field of chronobiology and may have implications in various domains, including sleep disorders, jet lag, and shift work adaptation, although these potential applications are beyond the scope of this description.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Targets BCR-ABL kinase to inhibit cell proliferation in CML. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Inhibits RAF kinases and VEGF receptors in cancer signaling. | ||||||
MDV3100 | 915087-33-1 | sc-364354 sc-364354A | 5 mg 50 mg | $245.00 $1051.00 | 7 | |
Acts as an androgen receptor antagonist in prostate cancer. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Inhibits JAK1/2 kinases to reduce cytokine signaling in MPNs. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Blocks EGFR kinase activity in non-small cell lung cancer. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Inhibits the proteasome, leading to cell death in myeloma. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $131.00 $651.00 | 7 | |
Targets mTOR to suppress cell growth in various cancers. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $156.00 | 5 | |
Inhibits BTK kinase in B-cell malignancies, disrupting signaling. | ||||||
Osimertinib | 1421373-65-0 | sc-507355 | 5 mg | $86.00 | ||
Selectively inhibits EGFR in T790M-mutant lung cancer. | ||||||
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $118.00 $337.00 $520.00 $832.00 $1632.00 | 10 | |
Binds to BCL-2, promoting apoptosis in leukemia cells. | ||||||